Growth on track, but margins softened by new capacity absorption

Revenue +16.7% YoY confirmed. Network EBITDA growth ~15% YoY plausible but not independently verified.

Delivered PAT ₹323 Cr (vs likely ~₹342 Cr prior year for -5.6% QoQ). Network figure excludes corporate costs.

Revenue drag acknowledged; ex-oncology growth 20% vs 5% with oncology. Strategic choice, not market loss.

Claim is based on post-acquisition quarter (₹19 Cr revenue). Turnaround plan credible; 12-month integration timeline stated.

Actually a DETERIORATION (87→95), not improvement. CGHS portal delays cited; collections improving June onwards.

Chemo drug discontinuation strategy, announced mid-Q3 FY26, materialized in Q1 with oncology share 26%→22%, YoY in-patient revenue ~₹4 Cr headwind. Will normalize Q3 onwards per mgmt.

Sector 56 Gurgaon (500 beds, end-CY26 start), Vaishali brownfield (₹425 Cr, FY30), Pune greenfield (450 beds, FY30, IOD received). Total 3000+ beds by FY30 vs prior ~2000-bed estimate.

Regulatory change (NMC draft allowing for-profit medical colleges) enables new line. ₹300 Cr capex, 150-seat college, 25-30% ROCE. Board in-principle approval; commercial launch FY27-28.

New CGHS portal launched; collections restarting June onwards. ₹140 Cr FY27 target on track (vs super-specialty rate stall in prior Q). September-October insurance renewals also include 6% price bump.

DSO extended to 95 days (from 87 prior year) due to CGHS portal delays. ₹250 Cr AR buildup YoY, hampering FCF conversion (56% vs prior 62-65% target). Expected to normalize as collections accelerate.

Oncology was our largest revenue source (25%+) with highest institutional/CGHS exposure (Delhi presence). Chemo drug discontinuation hit us harder. Normalization starts Q3 FY26 onwards, fully in Q4.

50-80% upside in both occupancy and ARPOB. Similar playbook as Lucknow, Noida. Will renovate, upgrade tech, clinical programs. Add 200-250 beds in Phase 2. Marginal profit now; will yield.

Standard brownfield trajectory: occupancy first (low ARPOB), revenue ramps next, EBITDA last. Break-even with occupancy, then EBITDA surpass revenue growth. Q2-Q3 of operations you see it (not Q1 itself).

GIPSA and others under negotiation. Sept-Oct renewals. Prior deal: 6% auto price revision in place. IRDAI discussions on inflation-linked increases. Expecting some price traction.

AR buildup ₹250 Cr QoQ due to CGHS/PSU lumpiness (DSO 87→95 days). ETR also up. CGHS portal now processing; should normalize.

No reassessment. We're efficient providers; any viable policy should favour us. If sector viability compressed, consolidation opportunity.

₹300 Cr per 150-seat college. 25-30% ROCE. Fund entirely through internal accruals. Start commercial ops over next few years; open to acquisitions to accelerate.

Institutional biz never profitable; contributes to fixed costs. Not particularly concerned. Part of business. Up-down lumpiness expected.

Pulled due to tactical competition sensitivity; some states have only one hospital. Will consider 'Others' bucketing instead.

It is coming down. Result of concerted effort to shift to retail/better-paying segments.

No. Would require 300K beds across top 3 (India has 100K today). Execution + capex challenges too high. Max can double every 4-5 yrs: 5K→10K→20K→40K best case. Gap persists.

Management expects continued double-digit growth driven by capacity ramp (Smart, Nanavati, Sector 56 Gurgaon, medical education). No numeric FY27 target disclosed.

OPM fell 26.8%→25.3% Q4→Q1 due to brownfield ramp. Similar to prior acquisitions (Lucknow, Noida): margin dips 1-2 quarters, recovers in 6-9 months as ARPOB rises and fixed cost absorption completes.

Board-approved pipeline with master plans filed/in progress. ₹337 Cr invested Q1. All funded via internal accruals + moderate leverage (target 2.5x net debt/EBITDA).

Parliamentary Standing Committee (176th report) flagged sector affordability concerns and recommended FDI restrictions. If enacted, could curb acquisition/foreign funding strategy. MD downplayed risk but acknowledged as policy uncertainty.

CGHS reimbursement cuts reducing institutional profitability. Institutions are loss-making but contribute to fixed costs. Any further rollback could force revenue reallocation or margin sacrifice.

Discontinued select high-value chemo drugs for institutional patients (post-Oct 2025 MOU with CGHS/insurance). Oncology share fell 26%→22%, dragging YoY revenue ~₹4 Cr. Will normalize Q3 FY27 onwards, but near-term headwind.

DSO extended 87→95 days due to CGHS/PSU lumpiness and new portal processing delays. ₹250 Cr AR buildup YoY. FCF conversion fell to 56% vs target 62-65%. If AR normalization delayed, capex funding and debt paydown could slip.

Max Smart and Nanavati at 80% occupancy Q1, but EBITDA ramp delayed (management trajectory: revenue ramp Q2-Q3, EBITDA ramp Q3+). Large capex pipeline (3000+ beds by FY30) relies on phased commissioning and ramp pace. Delays could push EBITDA recovery into FY28.

Kalinga (Bhubaneswar) at 50% occupancy, ₹35K ARPOB, ₹2 Cr EBITDA Q1. 12-month integration to renovate, upgrade tech, and drive ARPOB/occupancy uplift. Yerawada (Pune) put option liability; final stake acquisition contingent on disputed minority holders in UAE.